DOCSLIB.ORG

GASMET Extended Reference Library

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GASMET Extended Reference Library GASMET Extended Reference Library CAS Name CAS Name 100_00_5 Benzene, 1-chloro-4-nitro- 100_00_5 Benzene, 1-chloro-4-nitro- 100_02_7 4-Nitrophenol 100_02_7 4-Nitrophenol 100_06_1 4'-Methoxyacetophenone 100_06_1 4'-Methoxyacetophenone 100_10_7 p-N,N-Dimethylaminobenzaldehyde 100_10_7 p-N,N-Dimethylaminobenzaldehyde 100_11_8 p-Nitrobenzylbromide 100_11_8 p-Nitrobenzylbromide 100_14_1 p-Nitrobenzylchloride 100_14_1 p-Nitrobenzylchloride 100_17_4 Benzene, 1-methoxy-4-nitro- 100_17_4 Benzene, 1-methoxy-4-nitro- 100_18_5 1,4-Di-isopropylbenzene 100_18_5 1,4-Di-isopropylbenzene 100_19_6 Acetophenone, 4'-nitro- 100_19_6 Acetophenone, 4'-nitro- 100_25_4 1,4-Dinitrobenzene 100_25_4 1,4-Dinitrobenzene 100_27_6 Benzeneethanol, 4-nitro- 100_27_6 Benzeneethanol, 4-nitro- 100_29_8 Benzene, 1-ethoxy-4-nitro- 100_29_8 Benzene, 1-ethoxy-4-nitro- 100_36_7 1,2-Ethanediamine, N,N-diethyl- 100_36_7 1,2-Ethanediamine, N,N-diethyl- 100_37_8 Ethanol, 2-(diethylamino)- 100_37_8 Ethanol, 2-(diethylamino)- 100_39_0 Benzylbromide 100_39_0 Benzylbromide 100_40_3 Cyclohexene, 4-ethenyl- 100_40_3 Cyclohexene, 4-ethenyl- 100_41_4 Ethylbenzene 100_41_4 Ethylbenzene 100_44_7 Benzyl chloride 100_44_7 Benzyl chloride 100_46_9 Benzylamine 100_46_9 Benzylamine 100_47_0 Benzonitrile 100_47_0 Benzonitrile 100_50_5 3-Cyclohexene-1-carboxaldehyde 100_50_5 3-Cyclohexene-1-carboxaldehyde 100_51_6 Benzylalcohol 100_51_6 Benzylalcohol 100_52_7 Benzaldehyde 100_52_7 Benzaldehyde 100_53_8 Benzenemethanethiol 100_53_8 Benzenemethanethiol 100_55_0 Nicotinyl Alcohol 100_55_0 Nicotinyl Alcohol 100_60_7 Cyclohexanamine, N-methyl- 100_60_7 Cyclohexanamine, N-methyl- 100_61_8 Aniline, N-methyl- 100_61_8 Aniline, N-methyl- 100_64_1 Cyclohexanone oxime 100_64_1 Cyclohexanone oxime 100_66_3 Benzene, methoxy- 100_66_3 Benzene, methoxy- 100_71_0 2-Ethylpyridine 100_71_0 2-Ethylpyridine 100_74_3 Morpholine, 4-ethyl- 100_74_3 Morpholine, 4-ethyl- 100_79_8 1,3-Dioxolane-4-methanol, 2,2-dimethyl- 100_79_8 1,3-Dioxolane-4-methanol, 2,2-dimethyl- 100_80_1 3-Methylstyrene 100_80_1 3-Methylstyrene 100_84_5 Benzene, 1-methoxy-3-methyl- 100_84_5 Benzene, 1-methoxy-3-methyl- 100_86_7 2-Methyl-1-phenyl-2-propanol 100_86_7 2-Methyl-1-phenyl-2-propanol 100_92_5 Mephentermine 100_92_5 Mephentermine 100_97_0 Hexamethylenetetraamine 100_97_0 Hexamethylenetetraamine 1000_86_8 2,4-Dimethyl-1,3-pentadiene 1000_86_8 2,4-Dimethyl-1,3-pentadiene 1000_87_9 2,4-Dimethyl-2,3-pentadiene 1000_87_9 2,4-Dimethyl-2,3-pentadiene 1002_27_3 1,3,6-Heptatriene 1002_27_3 1,3,6-Heptatriene 1002_28_4 3-Hexyn-1-ol 1002_28_4 3-Hexyn-1-ol 1002_33_1 1,3-Octadiene 1002_33_1 1,3-Octadiene 1002_69_3 Decane, 1-chloro- 1002_69_3 Decane, 1-chloro- 1002_84_2 Pentadecanoic acid 1002_84_2 Pentadecanoic acid 10024_90_5 Acetophenone, 4'-methoxy-3'-methyl- 10024_90_5 Acetophenone, 4'-methoxy-3'-methyl- 10024_97_2 Nitrous Oxide 10024_97_2 Nitrous Oxide 1003_10_7 .gamma.-Thiobutyrolactone 1003_10_7 .gamma.-Thiobutyrolactone 1003_17_4 2,2-Dimethyltetrahydrofuran 1003_17_4 2,2-Dimethyltetrahydrofuran 1003_19_6 1,1-Diethylcyclopropane 1003_19_6 1,1-Diethylcyclopropane 1003_29_8 1H-Pyrrole-2-carboxaldehyde 1003_29_8 1H-Pyrrole-2-carboxaldehyde 1003_31_2 2-Thiophenecarbonitrile 1003_31_2 2-Thiophenecarbonitrile 1003_38_9 2,5-Dimethyltetrahydrofuran 1003_38_9 2,5-Dimethyltetrahydrofuran 1003_64_1 Ethylidenecyclohexane 1003_64_1 Ethylidenecyclohexane 1003_73_2 Pyridine, 3-methyl-, 1-oxide 1003_73_2 Pyridine, 3-methyl-, 1-oxide 10031_87_5 Acetic acid, 2-ethylbutyl ester 10031_87_5 Acetic acid, 2-ethylbutyl ester 1004_24_6 4-Methylenecyclohexylmethanol 1004_24_6 4-Methylenecyclohexylmethanol 10045_65_5 1H-Imidazole-2-carboxaldehyde, 1-(phenylmethyl)- 10045_65_5 1H-Imidazole-2-carboxaldehyde, 1-(phenylmethyl)- 1005_64_7 trans-1-Phenyl-1-butene 1005_64_7 trans-1-Phenyl-1-butene 10052_09_2 Nicotinamide, N,N-dipropyl-, 10052_09_2 Nicotinamide, N,N-dipropyl-, 10056_30_1 Morpholine, 2,6-dimethyl-4-isopentyl-, 10056_30_1 Morpholine, 2,6-dimethyl-4-isopentyl-, 1006_99_1 Benzothiazole, 5-chloro-2-methyl- 1006_99_1 Benzothiazole, 5-chloro-2-methyl- 10061_02_6 trans-1,3-Dichloropropene 10061_02_6 trans-1,3-Dichloropropene 1007_26_7 Neopentylbenzene 1007_26_7 Neopentylbenzene 1007_32_5 1-Phenyl-2-butanone 1007_32_5 1-Phenyl-2-butanone 1007_54_1 Ethanethiol, 2-benzylamino-, 1007_54_1 Ethanethiol, 2-benzylamino-, 1008_88_4 3-Phenylpyridine 1008_88_4 3-Phenylpyridine 1009_11_6 1-Butanone, 1-(4-hydroxyphenyl)- 1009_11_6 1-Butanone, 1-(4-hydroxyphenyl)- 1009_14_9 1-Phenyl-1-pentanone 1009_14_9 1-Phenyl-1-pentanone 1009_74_1 2,4,6-Triethyltriazine 1009_74_1 2,4,6-Triethyltriazine 1009_84_3 Pyridazine, 3-butylamino-6-chloro-, 1009_84_3 Pyridazine, 3-butylamino-6-chloro-, 10099_70_4 2-Butenedioic acid (Z)-, bis(1-methylethyl) ester 10099_70_4 2-Butenedioic acid (Z)-, bis(1-methylethyl) ester 101_05_3 Anilazine 101_05_3 Anilazine 101_08_6 Diperodon 101_08_6 Diperodon 101_18_8 3-Hydroxydiphenylamine 101_18_8 3-Hydroxydiphenylamine 101_21_3 Chlorpropham 101_21_3 Chlorpropham 101_37_1 2,4,6-Triallyloxy-1,3,5-triazine 101_37_1 2,4,6-Triallyloxy-1,3,5-triazine 101_43_9 2-Propenoic acid, 2-methyl-, cyclohexyl ester 101_43_9 2-Propenoic acid, 2-methyl-, cyclohexyl ester 101_48_4 Benzene, (2,2-dimethoxyethyl)- 101_48_4 Benzene, (2,2-dimethoxyethyl)- 101_53_1 Phenol, 4-(phenylmethyl)- 101_53_1 Phenol, 4-(phenylmethyl)- 101_55_3 Benzene, 1-bromo-4-phenoxy- 101_55_3 Benzene, 1-bromo-4-phenoxy- 101_72_4 1,4-Benzenediamine, N-(1-methylethyl)-N'-phenyl- 101_72_4 1,4-Benzenediamine, N-(1-methylethyl)-N'-phenyl- 101_76_8 Benzene, 1,1'-methylenebis[4-chloro- 101_76_8 Benzene, 1,1'-methylenebis[4-chloro- 101_77_9 4,4'-Methylenedianiline 101_77_9 4,4'-Methylenedianiline 101_81_5 Diphenylmethane 101_81_5 Diphenylmethane 101_84_8 Diphenyl ether 101_84_8 Diphenyl ether 101_85_9 Amyl cinnamic alcohol 101_85_9 Amyl cinnamic alcohol 101_86_0 Octanal, 2-(phenylmethylene)- 101_86_0 Octanal, 2-(phenylmethylene)- 101_97_3 Benzeneacetic acid, ethyl ester 101_97_3 Benzeneacetic acid, ethyl ester 1010_99_7 1,2-Benzenediol, 3-(1,1-dimethylethyl)-5-methyl- 1010_99_7 1,2-Benzenediol, 3-(1,1-dimethylethyl)-5-methyl- 10108_56_2 Cyclohexanamine, N-butyl- 10108_56_2 Cyclohexanamine, N-butyl- 1013_75_8 Carbamic acid, ethylphenyl-, ethyl ester 1013_75_8 Carbamic acid, ethylphenyl-, ethyl ester 10133_30_9 Benzo[b]thiophene-5-carboxaldehyde 10133_30_9 Benzo[b]thiophene-5-carboxaldehyde 10133_34_3 Benzo[b]thiophene, 4-nitro- 10133_34_3 Benzo[b]thiophene, 4-nitro- 10137_80_1 Aniline, N-(2-ethylhexyl)- 10137_80_1 Aniline, N-(2-ethylhexyl)- 10138_32_6 Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, ethyl ester 10138_32_6 Bicyclo[2.2.1]hept-5-ene-2-carboxylic acid, ethyl ester 10138_59_7 1,2-Cyclohexanedicarboxylic acid, diethyl ester 10138_59_7 1,2-Cyclohexanedicarboxylic acid, diethyl ester 1014_60_4 1,3-Ditertiarybutylbenzene 1014_60_4 1,3-Ditertiarybutylbenzene 1014_70_6 Simetryn 1014_70_6 Simetryn 10141_72_7 2-Methyltetrahydropyran 10141_72_7 2-Methyltetrahydropyran 10143_60_9 Heptane, 3,3'-[oxybis(methylene)]bis- 10143_60_9 Heptane, 3,3'-[oxybis(methylene)]bis- 102_04_5 2-Propanone, 1,3-diphenyl- 102_04_5 2-Propanone, 1,3-diphenyl- 102_06_7 1,3-Diphenylguanidine 102_06_7 1,3-Diphenylguanidine 102_11_4 N-Benzyl-N,N'-dimethylethylenediamine 102_11_4 N-Benzyl-N,N'-dimethylethylenediamine 102_16_9 Benzeneacetic acid, phenylmethyl ester 102_16_9 Benzeneacetic acid, phenylmethyl ester 102_17_0 Anisyl phenylacetate 102_17_0 Anisyl phenylacetate 102_18_1 1,2-Ethanediamine, N,N'-dimethyl-N,N'-bis(phenylmethyl)- 102_18_1 1,2-Ethanediamine, N,N'-dimethyl-N,N'-bis(phenylmethyl)- 102_19_2 Acetic acid, phenyl-, isopentyl ester 102_19_2 Acetic acid, phenyl-, isopentyl ester 102_22_7 Geranyl phenylacetate 102_22_7 Geranyl phenylacetate 102_25_0 Benzene, 1,3,5-triethyl- 102_25_0 Benzene, 1,3,5-triethyl- 102_27_2 Benzenamine, N-ethyl-3-methyl- 102_27_2 Benzenamine, N-ethyl-3-methyl- 102_29_4 Resorcinol Monoacetate 102_29_4 Resorcinol Monoacetate 102_45_4 Cyclopentamine 102_45_4 Cyclopentamine 102_46_5 Benzene, 4-(chloromethyl)-1,2-dimethyl- 102_46_5 Benzene, 4-(chloromethyl)-1,2-dimethyl- 102_47_6 Benzene, 1,2-dichloro-4-(chloromethyl)- 102_47_6 Benzene, 1,2-dichloro-4-(chloromethyl)- 102_62_5 (Hydroxymethyl)ethylene acetate 102_62_5 (Hydroxymethyl)ethylene acetate 102_69_2 1-Propanamine, N,N-dipropyl- 102_69_2 1-Propanamine, N,N-dipropyl- 102_70_5 Triallylamine 102_70_5 Triallylamine 102_76_1 Triacetin 102_76_1 Triacetin 102_77_2 Morpholine, 4-(2-benzothiazolylthio)- 102_77_2 Morpholine, 4-(2-benzothiazolylthio)- 102_79_4 Ethanol, 2,2'-(butylimino)bis- 102_79_4 Ethanol, 2,2'-(butylimino)bis- 102_82_9 Tributylamine 102_82_9 Tributylamine 102_85_2 Phosphorous acid, tributyl ester 102_85_2 Phosphorous acid, tributyl ester 102_97_6 Benzenemethanamine, N-(1-methylethyl)- 102_97_6 Benzenemethanamine, N-(1-methylethyl)- 10202_75_2 4-Allyl-1,6-heptadiene-4-ol 10202_75_2 4-Allyl-1,6-heptadiene-4-ol 10203_28_8 2-Dodecanol 10203_28_8 2-Dodecanol 10203_30_2 3-Dodecanol 10203_30_2 3-Dodecanol 10203_32_4 4-Dodecanol 10203_32_4 4-Dodecanol 10203_33_5 5-Dodecanol 10203_33_5 5-Dodecanol 10203_58_4 Diethyl isobutylmalonate 10203_58_4 Diethyl isobutylmalonate 10229_10_4 3-Pentyn-1-ol 10229_10_4 3-Pentyn-1-ol 10232_93_6 2-Butenedioic acid (Z)-, bis(2-methoxyethyl) ester 10232_93_6 2-Butenedioic acid (Z)-, bis(2-methoxyethyl) ester 1024_57_3 Heptachlor epoxide 1024_57_3 Heptachlor epoxide 1026_32_0 Acetic acid, (6-acetyl-4-chloro-m-tolyloxy)-, ethyl ester 1026_32_0 Acetic acid, (6-acetyl-4-chloro-m-tolyloxy)-, ethyl ester 1026_92_2 1,4-Benzenedicarboxylic
Load more

Recommended publications
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Download Author Version (PDF)
    RSC Advances This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/advances Page 1 of 12 RSC Advances RSC Advances RSCPublishing ARTICLE Label-free cell phenotypic profiling identifies pharmacologically active compounds in two Cite this: DOI: 10.1039/x0xx00000x Traditional Chinese Medicinal plants Xiuli Zhanga,‡, Huayun Dengb,‡, Yuansheng Xiaoa, Xingya Xuea, Ann M. Ferrieb, Received 00th April 2014, Elizabeth Tranb, Xinmiao Lianga,*, and Ye Fangb,* Accepted 00th April 2014 DOI: 10.1039/x0xx00000x Traditional Chinese Medicines (TCMs) are widely used in clinical practice and natural products have been a rich resource for drug discovery. Identification of pharmacologically www.rsc.org/ active chemical constituents is essential to the future of TCMs and natural product-based drug discovery.
    [Show full text]
  • QSAR Model for Androgen Receptor Antagonism
    s & H oid orm er o t n S f a l o S l c a Journal of i n e Jensen et al., J Steroids Horm Sci 2012, S:2 r n u c o e DOI: 10.4172/2157-7536.S2-006 J ISSN: 2157-7536 Steroids & Hormonal Science Research Article Open Access QSAR Model for Androgen Receptor Antagonism - Data from CHO Cell Reporter Gene Assays Gunde Egeskov Jensen*, Nikolai Georgiev Nikolov, Karin Dreisig, Anne Marie Vinggaard and Jay Russel Niemelä National Food Institute, Technical University of Denmark, Department of Toxicology and Risk Assessment, Mørkhøj Bygade 19, 2860 Søborg, Denmark Abstract For the development of QSAR models for Androgen Receptor (AR) antagonism, a training set based on reporter gene data from Chinese hamster ovary (CHO) cells was constructed. The training set is composed of data from the literature as well as new data for 51 cardiovascular drugs screened for AR antagonism in our laboratory. The data set represents a wide range of chemical structures and various functions. Twelve percent of the screened drugs were AR antagonisms; three out of six statins showed AR antagonism, two showed cytotoxicity and one was negative. The newly identified AR antagonisms are: Lovastatin, Simvastatin, Mevastatin, Amiodaron, Docosahexaenoic acid and Dilazep. A total of 874 (231 positive, 643 negative) chemicals constitute the training set for the model. The Case Ultra expert system was used to construct the QSAR model. The model was cross-validated (leave-groups-out) with a concordance of 78.4%, a specificity of 86.1% and a sensitivity of 57.9%.
    [Show full text]
  • Known Bioactive Library: Microsource 1 - US Drug Collection
    Known Bioactive Library: Microsource 1 - US Drug Collection ICCB-L ICCB-L Vendor Vendor Compound Name Bioactivity Source CAS Plate Well ID antifungal, inhibits Penicillium 2091 A03 Microsource 00200046 GRISEOFULVIN 126-07-8 mitosis in metaphase griseofulvum 3505-38-2, 486-16-8 2091 A04 Microsource 01500161 CARBINOXAMINE MALEATE antihistaminic synthetic [carbinoxamine] 2091 A05 Microsource 00200331 SALSALATE analgesic synthetic 552-94-3 muscle relaxant 2091 A06 Microsource 01500162 CARISOPRODOL synthetic 78-44-4 (skeletal) antineoplastic, 2091 A07 Microsource 00210369 GALLIC ACID insect galls 149-91-7 astringent, antibacterial 66592-87-8, 50370-12- 2091 A08 Microsource 01500163 CEFADROXIL antibacterial semisynthetic 2 [anhydrous], 119922- 89-9 [hemihydrate] Rheum palmatum, 2091 A09 Microsource 00211468 DANTHRON cathartic 117-10-2 Xyris semifuscata 27164-46-1, 25953-19- 2091 A10 Microsource 01500164 CEFAZOLIN SODIUM antibacterial semisynthetic 9 [cefazolin] glucocorticoid, 2091 A11 Microsource 00300024 HYDROCORTISONE adrenal glands 50-23-7 antiinflammatory 64485-93-4, 63527-52- 2091 A12 Microsource 01500165 CEFOTAXIME SODIUM antibacterial semisynthetic 6 [cefotaxime] 2091 A13 Microsource 00300029 DESOXYCORTICOSTERONE ACETATE mineralocorticoid adrenocortex 56-47-3 58-71-9, 153-61-7 2091 A14 Microsource 01500166 CEPHALOTHIN SODIUM antibacterial semisynthetic [cephalothin] 2091 A15 Microsource 00300034 TESTOSTERONE PROPIONATE androgen, antineoplastic semisynthetic 57-85-2 24356-60-3, 21593-23- 2091 A16 Microsource 01500167 CEPHAPIRIN SODIUM
    [Show full text]
  • Niacin Alternatives for Dyslipidemia: Fool's Gold Or Gold Mine? Part II
    Curr Atheroscler Rep (2016) 18: 17 DOI 10.1007/s11883-016-0570-9 NONSTATIN DRUGS (E. DEGOMA, SECTION EDITOR) Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics Harsh Goel1 & Richard L. Dunbar2,3,4,5,6 Published online: 1 March 2016 # The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Two cardiovascular outcome trials established ni- predecessors. Thus, shrewd developers could effectively acin 3 g daily prevents hard cardiac events. However, as tap into a gold mine at the grave of the ER alternative. The detailed in part I of this series, an extended-release (ER) GPR109A receptor was discovered a decade ago, leading to alternative at only 2 g nightly demonstrated no comparable a large body of evidence commending the niacin pathway to benefits in two outcome trials, implying the alternative is a lower cardiovascular risk beyond statins. While mediating not equivalent to the established cardioprotective regimen. niacin’s most prominent adverse effects, GPR109A also Since statins leave a significant treatment gap, this presents seems to mediate anti-lipolytic, anti-inflammatory, and a major opportunity for developers. Importantly, the anti-atherogenic effects of niacin. Several developers are established regimen is cardioprotective, so the pathway is investing heavily in novel strategies to exploit niacin’sther- likely beneficial. Moreover, though effective, the apeutic pathways. These include selective GPR109A recep- established cardioprotective regimen is cumbersome, limit- tor agonists, niacin prodrugs, and a niacin metabolite, with ing clinical use. At the same time, the ER alternative has encouraging early phase human data.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0053975A1 Bova Et Al
    US 2004.0053975A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0053975A1 Bova et al. (43) Pub. Date: Mar. 18, 2004 (54) COMBINATIONS OF HMG-COA tor, which are useful for altering lipid levels in Subjects REDUCTASE INHIBITORS AND NCOTINC Suffering from, for example, hyperlipidemia and atheroscle ACID COMPOUNDS AND METHODS FOR rosis, without causing drug-induced hepatotoxicity, myopa TREATING HYPELPIDEMIA ONCE A DAY thy or rhabdomyolysis. The present invention also relates to AT NIGHT methods of altering Serum lipids in Subjects to treat, for example, hyperlipidemia in hyperlipidemics, lipidemia in (76) Inventors: David J. Bova, Boca Raton, FL (US); normolipidemics diagnosed with or predisposed to cardio Josephine Dunne, Plantation, FL (US) vascular disease, and atherosclerosis, by administering Such Correspondence Address: oral Solid pharmaceutical combinations once per day as a Karen J. Messick Single dose during the evening hours, without causing drug Kos Pharmaceuticals, Inc. induced hepatotoxicity, myopathy or rhabdomyolysis, or 25th Floor without causing in at least an appreciable number of indi 1001 Brickell Bay Drive viduals drug-induced hepatotoxicity, myopathy or rhab Miami, FL 33131 (US) domyolysis to Such a level that discontinuation of Such therapy would be required. More particularly, the present (21) Appl. No.: 10/260,027 invention concerns oral Solid pharmaceutical combinations comprised of, for example, (1) an HMG-CoA reductase (22) Filed: Sep. 2, 2003 inhibitor for immediate or extended release, (2) nicotinic acid, a nicotinic acid compound or mixtures thereof and (3) Related U.S. Application Data a Swelling agent to form a Sustained release composition for extended release of the nicotinic acid or nicotinic acid (63) Continuation of application No.
    [Show full text]
  • Trends in Lipid-Modifying Agent Use in 83 Countries
    medRxiv preprint doi: https://doi.org/10.1101/2021.01.10.21249523; this version posted January 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Trends in lipid-modifying agent use in 83 countries Authors (ORCID) Joseph E Blais (0000-0001-7895-198X)1; Yue Wei (NA)1; Kevin KW Yap (NA)2; Hassan Alwafi (NA)3; Tian-Tian Ma (0000-0003-1361-4055)3; Ruth Brauer (0000- 0001-8934-347X)3; Wallis CY Lau (0000-0003-2320-0470)3; Kenneth KC Man (0000- 0001-8645-1942)3; Chung Wah Siu (0000-0002-5570-983X)4; Kathryn C Tan (0000- 0001-9037-0416)5; Ian CK Wong (0000-0001-8242-0014)1,3; Li Wei (0000-0001- 8840-7267)3; Esther W Chan (0000-0002-7602-9470)1 Affiliations 1 Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China 2 Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China 3 Research Department of Practice and Policy, UCL School of Pharmacy, London, UK 4 Division of Cardiology, Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China 5 Department of Medicine, University of Hong Kong, Hong Kong Special Administrative Region, China Correspondence Esther W Chan, PhD Centre for Safe Medication Practice and Research Department of Pharmacology and Pharmacy NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Under-Utilisation of Preventive Medication in Patients with Cardiovascular Disease Is Greatest in Younger Age Groups (PREDICT-CVD 15)
    ORIGINAL SCIENTIFIC PAPERS QUANTItatIVE RESEARCH Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15) Suneela Mehta MBChB, MPH;1 Sue Wells MBChB, MPH, PhD;1 Tania Riddell BSc, MBChB, MPH;1 Andrew 1 Section of Epidemiology Kerr MA, MBChB;2 Romana Pylypchuk MSc, MPH;1 Roger Marshall BSc, MSc, PhD;1 Shanthi Ameratunga and Biostatistics, School of Population Health, The 1 3 1 MBChB, MPH, PhD; Wing Cheuk Chan MBChB, MPH; Simon Thornley MBChB, MPH; Sue Crengle University of Auckland, MBChB, MPH, PhD;4 Jeff Harrison BSc (Hons), PhD;5 Paul Drury MA MB BChir;6 C Raina Elley MBChB, PhD;7 Auckland, New Zealand Fionna Bell MBChB, MPH;8 Rod Jackson MBChB, PhD1 2 Middlemore Hospital, Counties Manukau District Health Board, Auckland ABSTRACT 3 Health Intelligence Unit, Counties Manukau District INtroductioN: Blood pressure–lowering (BPL) and lipid-lowering (LL) medications together reduce Health Board, Auckland estimated absolute five-year cardiovascular disease (CVD) risk by >40%. International studies indicate 4 that the proportion of people with CVD receiving pharmacotherapy increases with advancing age. Te Kupenga Hauora Maori, School of Population Health, Aim: To compare BPL and LL medications, by sociodemographic characteristics, for patients with known The University of Auckland, Auckland CVD in primary care settings. 5 Division of MethodS: The study population included patients aged 35–74 with known CVD assessed in primary Pharmacotherapy, School of care from July 2006 to October 2009 using a web-based computerised decision support system (PRE- Pharmacy, The University of DICT) for risk assessment and management.
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
    1111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (io) Patent No.: US 9,526,824 B2 Ferrari et al. (45) Date of Patent: Dec. 27, 2016 (54) NANOCHANNELED DEVICE AND RELATED (52) U.S. Cl. METHODS CPC .............. A61M 5/00 (2013.01); A61K 9/0097 (2013.01); A61M37/00 (2013.01); (71) Applicants:The Board of Regents of the (Continued) University of Texas System, Austin, TX (US); The Ohio State University (58) Field of Classification Search Research Foundation, Columbus, OH CPC ............. B81C 1/00444; B81C 1/00476; B81C (US) 1/00119; BO1D 67/0034; YIOS 148/05 (Continued) (72) Inventors: Mauro Ferrari, Houston, TX (US); Xuewu Liu, Sugar Land, TX (US); (56) References Cited Alessandro Grattoni, Houston, TX (US); Daniel Fine, Austin, TX (US); U.S. PATENT DOCUMENTS Randy Goodall, Austin, TX (US); Sharath Hosali, Austin, TX (US); 3,731,681 A 5/1973 Blackshear et al. Ryan Medema, Pflugerville, TX (US); 3,921,636 A 11/1975 Zaffaroni Lee Hudson, Elgin, TX (US) (Continued) (73) Assignees: The Board of Regents of the FOREIGN PATENT DOCUMENTS University of Texas System, Austin, TX (US); The Ohio State University CN 1585627 2/2005 Research Foundation, Columbus, OH DE 10 2006 014476 7/2007 (US) (Continued) (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 784 days. "The Economic Costs of Drug Abuse in the United States," www. whitehousedrugpolicy.gov, Sep. 2001. (21) Appl. No.: 13/875,871 (Continued) (22) Filed: May 2, 2013 Primary Examiner Binh X Tran (65) Prior Publication Data (74) Attorney, Agent, or Firm Parker Highlander PLLC US 2013/0240483 Al Sep.
    [Show full text]